AKT1 and relapsing-remitting multiple sclerosis: These data suggest that in vivo FTY720 treatment inhibits the Th1‐like phenotype in RRMS patients by targeting the PI3K/AKT/mTORC1 pathway and rebalancing mitochondrial metabolism to reverse mitochondrial uncoupling.